Physician profile
Deborah Popowich
NPI 1629147913
$3,143.73
in general payments reported to CMS, 2019-2025
15 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $562 · 2021: $448 · 2022: $234 · 2023: $590 · 2024: $460 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,184.14 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $343.71 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $215.79 | 2023-2024 | |
| Amarin Pharma, INC. | $202.34 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.79 | 2019-2021 | |
| Novo Nordisk INC | $182.46 | 2020-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $167.24 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $155.72 | 2019-2024 | Airsupra |
| Kowa Pharmaceuticals America, INC. | $145.71 | 2019-2020 | |
| Pfizer INC. | $142.44 | 2019-2025 | |
| Exact Sciences Corporation | $52.83 | 2023 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $48.40 | 2023 | Ingrezza |
| Abbott Laboratories | $43.84 | 2025 | Jot Dx |
| Qiagen, LLC | $39.34 | 2024 | |
| Gilead Sciences, INC. | $22.98 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Popowich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.